Filter results
You can narrow down the results using the filters
Audience
Results
Displaying 26 - 1 of 26 results-
Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment
This paper provides guidance on the evidence needed to evaluate immunohistochemistry (IHC) testing for mismatch repair deficiency (dMMR) in colorectal cancer and many other types of tumours, to access pembrolizumab treatment.